Sustained Repigmentation in Vitiligo and Leukodermas Using Melanocyte–Keratinocyte Transplantation: 7 Years of Data
Issued Date
2024-01-01
Resource Type
eISSN
11787015
Scopus ID
2-s2.0-85209194454
Journal Title
Clinical, Cosmetic and Investigational Dermatology
Volume
17
Start Page
2447
End Page
2457
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical, Cosmetic and Investigational Dermatology Vol.17 (2024) , 2447-2457
Suggested Citation
Nuntawisuttiwong N., Yothachai P., Paringkarn T., Chaiyabutr C., Wongpraparut C., Silpa-Archa N. Sustained Repigmentation in Vitiligo and Leukodermas Using Melanocyte–Keratinocyte Transplantation: 7 Years of Data. Clinical, Cosmetic and Investigational Dermatology Vol.17 (2024) , 2447-2457. 2457. doi:10.2147/CCID.S485421 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/102119
Title
Sustained Repigmentation in Vitiligo and Leukodermas Using Melanocyte–Keratinocyte Transplantation: 7 Years of Data
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: The autologous non-cultured melanocyte–keratinocyte transplantation procedure (MKTP) has emerged as an effective treatment for various types of vitiligo and leukodermas. However, there is limited data on the long-term outcomes of the MKTP, especially in Thai patients. Objective: To assess the long-term efficacy and safety of the MKTP in patients with vitiligo and other leukodermas. Methods: This retrospective observational study analyzed data from 23 patients who underwent the MKTP for vitiligo and other leukodermas at the Siriraj MKTP Clinic, Thailand, and had a follow-up period exceeding 12 months. Clinical characteristics and MKTP specifics were evaluated. Repigmentation outcomes were assessed using the Vitiligo Area Scoring Index (VASI). Results: Of the 23 patients (24 treated lesions), 78.3% had segmental vitiligo, while the others had nevus depigmentosus, nonseg-mental vitiligo, or piebaldism. Most lesions (70.8%) were located on the face. At the 12-month follow-up, repigmentation showed an 80.8% ± 19.3% VASI improvement, which was sustained over 84 months with an 80%–90% VASI improvement. There was no statistically significant difference in repigmentation outcomes between facial and non-facial lesions. Conclusion: The MKTP demonstrated long-term efficacy and safety in treating vitiligo and other leukodermas, with sustained repigmentation over 84 months. These findings support the use of the MKTP as an effective treatment option for patients with refractory vitiligo and leukodermas, particularly within Thai populations.